Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
  • Mateos, Maria-Victoria
  • Bahlis, Nizar
  • Perrot, Aurore
  • Nooka, Ajay
  • Lu, Jin
  • ... Kim, Kihyun
  • 외 38명
Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0
제목
Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
저자
Mateos, Maria-VictoriaBahlis, NizarPerrot, AuroreNooka, AjayLu, JinPawlyn, CharlotteMina, RobertoCaeiro, GastonKentos, AlainHungria, VaniaReece, DonnaNiu, TingMylin, AnneHansen, CharlotteTeipel, RaphaelBesemer, BrittaDimopoulos, MeletiosZamagni, ElenaYoshihara, SatoshiKim, KihyunMin, Chang-KiGeerts, PaulusVan Leeuwen-Segarceanu, ElenaTyczynska, AgataReguera, Juan LuisJohansson, MagnusHansson, MarkusTurgut, MehmetGrey, MarkSidana, SurbhiRodriguez-Otero, PaulaMartinez-Lopez, JoaquinHashmi, HamzaCarson, RobinKobos, RachelSun, WeiliLantz, KristenSeifert, AnneBriseno-Toomey, DebbieO'Rourke, LisaRubin, MariaVieyra, DiegoKang, LijuanCosta, Luciano
DOI
10.1182/blood-2025-LBA-6
발행일
2025-11-24
유형
Meeting Abstract
저널명
Blood
146
페이지
LBA6 ~ LBA8